A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
| 适应症 | Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Non-Small-Cell Lung Carcinoma |
|---|---|
| 分期 | 2期 |
| 申办方 | Joseph J. Cullen, MD, FACS |
| 状态 | 进行中（已停止招募） |
| 受试者人数 | 43 人 |
| 干预（药物） | Radiation Therapy, Paclitaxel, Carboplatin, Ascorbic Acid |
| 开始日期 | 2018年11月16日 |
| 完成日期 | 2025年7月15日 |
| 结果公布日 | 2026年7月31日 |
摘要
This clinical trial evaluates adding high-dose ascorbate (vitamin C) to a standard therapy for non-small cell lung cancer. The standard therapy is radiation therapy combined with carboplatin and paclitaxel (types of chemotherapy). All subjects will receive high-dose ascorbate in addition to the standard therapy.
Progression Rate at the Completion of Radiation and Chemotherapy
| ChemoRT + Ascorbate | 6 Participants |
|---|
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients W — AstraZeneca
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With — National Cancer Institute (NCI)
- Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Pos — National Cancer Institute (NCI)
- Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage I — National Cancer Institute (NCI)
- Premedication to Reduce Amivantamab Associated Infusion Related Reactions — Janssen Research & Development, LLC
- A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab — Janssen Research & Development, LLC